DK175190B1 - Anvendelse af en angiotensin-konverterende enzyminhibitorforbindelse og farmaceutisk præparat til behandling af progressivt nyresvigt - Google Patents

Anvendelse af en angiotensin-konverterende enzyminhibitorforbindelse og farmaceutisk præparat til behandling af progressivt nyresvigt Download PDF

Info

Publication number: DK175190B1
Authority: DK; Denmark
Prior art keywords: phenylpropyl; alanyl; proline; ethoxycarbonyl; angiotensin
Prior art date: 1984-05-03

Application number

DK198501979A

Other languages

Danish (da)

English (en)

Other versions

DK197985D0 (da

DK197985A (da

Inventor

Ronald D Smith

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-05-03

Filing date

1985-05-02

Publication date

2004-07-05

1985-05-02 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1985-05-02 Publication of DK197985D0 publication Critical patent/DK197985D0/da

1985-11-04 Publication of DK197985A publication Critical patent/DK197985A/da

2004-07-05 Application granted granted Critical

2004-07-05 Publication of DK175190B1 publication Critical patent/DK175190B1/da

Links

239000005541 ACE inhibitor Substances 0.000 title claims description 21
150000001875 compounds Chemical class 0.000 title claims description 20
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title claims description 16
201000006370 kidney failure Diseases 0.000 title claims description 13
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 title claims description 8
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 12
208000017169 kidney disease Diseases 0.000 claims description 9
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims description 5
-1 3-mercapto-2-methyl-l-oxopropyl Chemical group 0.000 claims description 4
208000001647 Renal Insufficiency Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
230000000750 progressive effect Effects 0.000 claims description 4
102000005862 Angiotensin II Human genes 0.000 claims description 3
101800000733 Angiotensin-2 Proteins 0.000 claims description 3
108010016626 Dipeptides Proteins 0.000 claims description 3
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 3
229950006323 angiotensin ii Drugs 0.000 claims description 3
125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
DYWSVUBJGFTOQC-QMMMGPOBSA-N (2s)-2-ethylheptanoic acid Chemical compound CCCCC[C@H](CC)C(O)=O DYWSVUBJGFTOQC-QMMMGPOBSA-N 0.000 claims description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 2
AYQMNFRCBKOMIA-UHFFFAOYSA-N 1-benzazepin-2-one Chemical compound O=C1C=CC=C2C=CC=CC2=N1 AYQMNFRCBKOMIA-UHFFFAOYSA-N 0.000 claims description 2
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
208000033679 diabetic kidney disease Diseases 0.000 claims description 2
125000004344 phenylpropyl group Chemical group 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
229960002429 proline Drugs 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 3
108010064733 Angiotensins Proteins 0.000 claims 1
102000015427 Angiotensins Human genes 0.000 claims 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
125000001980 alanyl group Chemical group 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
239000002532 enzyme inhibitor Substances 0.000 claims 1
229940125532 enzyme inhibitor Drugs 0.000 claims 1
241000700159 Rattus Species 0.000 description 17
210000003734 kidney Anatomy 0.000 description 10
206010020772 Hypertension Diseases 0.000 description 9
201000001474 proteinuria Diseases 0.000 description 9
230000001434 glomerular Effects 0.000 description 8
108010061435 Enalapril Proteins 0.000 description 7
229960000873 enalapril Drugs 0.000 description 7
230000006378 damage Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000000004 hemodynamic effect Effects 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 3
231100000853 glomerular lesion Toxicity 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
210000000885 nephron Anatomy 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
101800000734 Angiotensin-1 Proteins 0.000 description 2
102400000344 Angiotensin-1 Human genes 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
108090000783 Renin Proteins 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
210000005086 glomerual capillary Anatomy 0.000 description 2
230000024924 glomerular filtration Effects 0.000 description 2
206010061989 glomerulosclerosis Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000036454 renin-angiotensin system Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000022461 Glomerular disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
206010062104 Renal mass Diseases 0.000 description 1
201000003099 Renovascular Hypertension Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241001275117 Seres Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
231100000852 glomerular disease Toxicity 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
238000010606 normalization Methods 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
125000006247 phenyl propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000036584 pressor response Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
239000005060 rubber Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000002966 stenotic effect Effects 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK198501979A 1984-05-03 1985-05-02 Anvendelse af en angiotensin-konverterende enzyminhibitorforbindelse og farmaceutisk præparat til behandling af progressivt nyresvigt DK175190B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60672584A	1984-05-03	1984-05-03
US60672584		1984-05-03

Publications (3)

Publication Number	Publication Date
DK197985D0 DK197985D0 (da)	1985-05-02
DK197985A DK197985A (da)	1985-11-04
DK175190B1 true DK175190B1 (da)	2004-07-05

Family

ID=24429205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198501979A DK175190B1 (da)	1984-05-03	1985-05-02	Anvendelse af en angiotensin-konverterende enzyminhibitorforbindelse og farmaceutisk præparat til behandling af progressivt nyresvigt

Country Status (5)

Country	Link
EP (1)	EP0160307A3 (fr)
JP (1)	JPH075482B2 (fr)
AU (1)	AU569789B2 (fr)
DK (1)	DK175190B1 (fr)
ES (1)	ES9500002A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD248961A1 (de) *	1984-05-22	1987-08-26	Akad Wissenschaften Ddr	Verfahren zur herstellung wundheilungsfoerdernder praeparationen
CA1313724C (fr) *	1987-02-19	1993-02-16	Shizuo Saito	Derives d'acides amines utilises comme antihypertensifs
US5210079A (en) *	1988-01-07	1993-05-11	E. I. Du Pont De Nemours And Company	Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5136044A (en) *	1988-04-04	1992-08-04	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	N2 -carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinolpril using the compound
JPH01254651A (ja) *	1988-04-04	1989-10-11	Kanegafuchi Chem Ind Co Ltd	Ｎ↑２−（１−カルボキシ−３−フエニルプロピル）−ｌ−リジン誘導体及び該化合物を用いるリジノプリルの製造法
US5504080A (en) *	1992-10-28	1996-04-02	Bristol-Myers Squibb Co.	Benzo-fused lactams
AU7186094A (en) *	1993-06-30	1995-01-24	Ciba-Geigy Ag	Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
FR2733911B1 (fr) *	1995-05-09	1998-05-29	Takeda Chemical Industries Ltd	Composition pharmaceutique pour maladies renales ou cardio-vasculaires
WO1997011717A1 (fr) *	1995-09-27	1997-04-03	Novartis Ag	Traitement de l'insuffisance renale chronique et progressive

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL58849A (en) *	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
EP0050800B2 (fr) *	1980-10-23	1995-06-07	Schering Corporation	Dipeptides carboxyalcoyliques, procédés pour les préparer et compositions pharmaceutiques les contenant

1985
- 1985-04-29 AU AU41781/85A patent/AU569789B2/en not_active Expired
- 1985-04-30 ES ES542756A patent/ES9500002A1/es active Pending
- 1985-05-02 EP EP85105336A patent/EP0160307A3/fr not_active Withdrawn
- 1985-05-02 JP JP60093942A patent/JPH075482B2/ja not_active Expired - Lifetime
- 1985-05-02 DK DK198501979A patent/DK175190B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPS6117520A (ja)	1986-01-25
JPH075482B2 (ja)	1995-01-25
DK197985D0 (da)	1985-05-02
EP0160307A2 (fr)	1985-11-06
ES9500002A1 (es)	1995-05-16
EP0160307A3 (fr)	1989-03-22
DK197985A (da)	1985-11-04
AU4178185A (en)	1985-11-07
AU569789B2 (en)	1988-02-18

Legal Events

Date	Code	Title	Description
2005-05-23	PUP	Patent expired

Publication	Publication Date	Title
US8722626B2 (en)	2014-05-13	Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition
RU2146522C1 (ru)	2000-03-20	Фармацевтический препарат
US4656188A (en)	1987-04-07	Ace inhibitors in macular degeneration
US5238924A (en)	1993-08-24	Treatment of renal diseases with ace inhibitors
JPH05194272A (ja)	1993-08-03	鬱血性心不全治療薬
Holdaas et al.	1998	Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
JP2014530212A5 (fr)	2015-11-12
JPH07504659A (ja)	1995-05-25	Ａｃｅ阻害剤及び利尿剤の併用
US20070213259A1 (en)	2007-09-13	Method for stabilizing blood pressure in hemodialysis subjects
Mason	1990	Angiotensin-converting enzyme inhibitors and renal function
JP3336331B2 (ja)	2002-10-21	新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉを使用する薬学的組成物
Conen et al.	1993	Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor
EP0160307A2 (fr)	1985-11-06	Inhibiteur de l'enzyme transformant l'angiotensine utiles dans le traitement des maladies rénales
Pedrinelli	1997	Microalbuminuria in essential hypertension. A marker of systemic vascular damage?
JPH0912475A (ja)	1997-01-14	虚血−再灌流障害の予防および治療薬
Malgor et al.	1969	Antagonism of angiotensin by hydralazine on renal blood flow and erythropoietin production
Böhler et al.	1992	Effect of nifedipine and captopril on glomerular hyperfiltration in normotensive man
Windt et al.	2006	Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy
Holdaas et al.	1995	Contrasting effects of angiotensin converting inhibitor and alpha‐1‐antagonist on albuminuria in insulin‐dependent diabetes mellitus patients with nephropathy
INSIPIDUS	2005	Lithium-Induced Kidney Disease
WO2026090251A1 (fr)	2026-04-30	Procédés pour améliorer les résultats de traitement chez des patients subissant une ultrafiltration
SU1437025A1 (ru)	1988-11-15	Способ лечени гепаторенальной формы лептоспироза
TAKAHASHI et al.	1993	Influence of factors in the digestive tract on the progression of chronic renal failure
RU2425671C1 (ru)	2011-08-10	Способ коррекции нарушений функции почек у больных стабильной стенокардией в сочетании с гипертонической болезнью
RU2119356C1 (ru)	1998-09-27	Способ лечения тяжелых форм глпс